About Us
What We Do
The Natal IPSCs Group is built on a differentiated technology platform to generate induced pluripotent stem cells or IPSCs from perinatal sources such as amniotic fluid, placenta and placental membranes, umbilical cord and Wharton’s jelly.
Here, we believe that through proprietary pre-selection and expansion technology, we will be able to generate IPSCs that are superior to current standard global approaches from generic sources
Research shows natal-derived cells efficiently generate stable, pluripotent iPSCs, making them a valuable resource for regenerative medicine and developmental research
Key Aspects of Natal/Neonatal iPSCs
01
High efficency
Neonatal tissues, such as umbilical cord blood or dental pulp, provide a rich source of somatic cells that are easily reprogrammed into iPSCs with high efficiency.
02
Reduced Aging Markers
Derived from young (“natal”) sources, these iPSCs show fewer aging markers such as longer telomeres and lower DNA damage, enhancing their long-term self-renewal and culture stability.
03
Reduced Epigenetic Memory
Natal-derived iPSCs have a more “blank slate” epigenome, enabling more efficient differentiation than adult cells that may retain epigenetic memory.
04
Applications
Model developmental diseases.
Generate disease specific cell lines.
Produce immune-matched therapies.
Leverage cord blood for
partial HLA matching.
Strategic Roadmap
Proprietary MSC Therapeutics
1
Wound Healing: Diabetic foot ulcers, C-section & vaginal laceration recovery
2
Postpartum Care: Treatment for liver disease, lung disease, and inflammatory disorders
3
Maternal Health: Addressing intrauterine and pregnancy-related disorders
4
Regeneration: Postpartum hematopoietic (blood) system recovery
Specialized Bio-Manufacturing
1
Flagship Product: iPSC-derived human breast milk tissue
2
Market Need: Mass-market “on-demand” production for premature infants
3
Impact: High-purity, scalable alternative to donor milk and formula